Quality Control and Quality Assurance in Pharmaceutical Industry

The international methods for determining the amount of geotaxis impurities (residual solvents and different inorganic and organic impurities) in pharmaceuticals are presented in this succinct review. Due to national and international requirements, it is now required to disclose both the purity and impurity profiles of a given pharmaceutical product. These factors, as well as the importance of pharmaceutical quality, efficacy, and safety, are covered, along with the types of impurities, their sources, their control, and regulatory considerations. One of the requirements for the provision of any nation's healthcare system is the availability of high-quality critical medications, since subpar medications have the potential to cause harm or even death to users. Even in very minute amounts, the presence of undesirable compounds in a given medication may affect both its safety and effectiveness. A pharmaceutical is a dynamic product, unlike those in other sectors, and its color, consistency, weight, and even chemical identity can vary between production and final consumption. As a result, pharmaceutical quality has long been a global concern and is currently gaining significant attention from regulatory bodies. Pharmaceutical product impurities are a major concern because of the potential harm they may do to medicine stability and shelf life in addition to the intrinsic toxicity of some contaminants. Impurities in pharmaceutical and drug products are undesirable substances (organic, inorganic, and residual solvents) that are either added or developed during formulation, age, or remain with the active pharmaceutical ingredients (APIs). The most prevalent impurities in all APIs are organic ones, which, even with appropriate handling, are naturally incorporated during the multi-step synthesis process.